Tag:
safinamide
Latest Headlines
Latest Headlines
Merck Serono returns rights to Parkinson's drug to Newron
Merck Serono has decided that the experimental Parkinson's disease drug safinamide won't be as strong a commercial drug as once thought. The company, a unit of Germany's Merck KGaA, has handed back
Safinamide shows promising Ph3 results against dyskinesia
Merck Serono and Newron Pharmaceuticals may have a promising new add-on treatment for Parkinson's disease sufferers. According to data from an extension of a previous Phase III trial, the company's
